TRACON Pharmaceuticals, Inc. Announces Intention of Ted Wang Not to Stand for Reelection to the Board of Directors at the Annual Meeting of Stockholders
April 10, 2019 at 06:09 am
Share
On April 5, 2019, Ted Wang informed TRACON Pharmaceuticals, Inc. that he does not intend to stand for reelection to the Board of Directors at the Company’s 2019 annual meeting of stockholders. Dr. Wang intends to continue serving as a director until the expiration of his term at the 2019 annual meeting.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
TRACON Pharmaceuticals, Inc. Announces Intention of Ted Wang Not to Stand for Reelection to the Board of Directors at the Annual Meeting of Stockholders
TRACON PHARMACEUTICALS, INC. 
